Announced Sun, 23 Aug, 2026 · 24:39 IST
USFDA approves Line 3 at Spokane contract manufacturing facility
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+2.1%1-day move
₹877.00
prior close
₹912.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.6-3.1-2.9-2.2+2.1+1.1+0.2+0.3+1.1+2.6+14.6+21.3——
Up moveDown movePending
AI summary
USFDA approved commercial batch manufacturing of the first product on Line 3, a new Isolator based fill and finish line at Jubilant HollisterStier LLC's contract manufacturing facility in Spokane, USA. JHS is a wholly owned subsidiary of the company through Jubilant Pharma Holding Inc. and Jubilant Pharma Limited, Singapore. The facility makes sterile injectables and ophthalmics for global pharma and biopharma clients.
Likely market impact
Positive. USFDA clearance unlocks commercial output on the new line, expanding contract manufacturing capacity and future revenue potential.